InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLL
The paper in STTT concludes that orelabrutinib significantly prolongs PFS and reduces the risk of disease progression or death by 68%.
The paper in STTT concludes that orelabrutinib significantly prolongs PFS and reduces the risk of disease progression or death by 68%.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.